TrianglePUBLICATIONS · 30351457
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer
- Publication date
- 2019 Jan 15
- First author
- Malempati S
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Malempati S
- type
- Author
- name
- Weigel BJ
- type
- Author
- name
- Chi YY
- type
- Author
- name
- Tian J
- type
- Author
- name
- Anderson JR
- type
- Author
- name
- Parham DM
- type
- Author
- name
- Teot LA
- type
- Author
- name
- Rodeberg DA
- type
- Author
- name
- Yock TI
- type
- Author
- name
- Shulkin BL
- type
- Author
- name
- Spunt SL
- type
- Author
- name
- Meyer WH
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Malempati S
- type
- Author
- name
- Weigel BJ
- type
- Author
- name
- Chi YY
- type
- Author
- name
- Tian J
- type
- Author
- name
- Anderson JR
- type
- Author
- name
- Parham DM
- type
- Author
- name
- Teot LA
- type
- Author
- name
- Rodeberg DA
- type
- Author
- name
- Yock TI
- type
- Author
- name
- Shulkin BL
- type
- Author
- name
- Spunt SL
- type
- Author
- name
- Meyer WH
- type
- Author
- bibliography ids
- nci-bib-e9213e71d050e9e7e176914a
- book metadata
- content sha256
- 5eef35c02e85f4b6c5f5a5fecab9e7e835adf1f3eb857fb86e5fd5d509ad0934
- document type
- citation
- dois
- 10.1002/cncr.31770
- electronic publication date
- display
- 2018 Oct 23
- precision
- day
- year
- 2018
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:30351457
- immutable id
- pubmed:30351457@5eef35c02e85f4b6c5f5a5fecab9e7e835adf1f3eb857fb86e5fd5d509ad0934
- journal
- abbreviation
- Cancer
- issn electronic
- 1097-0142
- issn print
- 0008-543X
- issue
- 2
- name
- Cancer
- nlm unique id
- 0374236
- pages
- 290-297
- volume
- 125
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 30351457
- provenance
- batch id
- 438b2803888025c6cf56
- provider
- NCBI PubMed ESummary
- record sha256
- 461d97d6d1a5d276a743eaa2b2a5ee2d61475f2ed1139725af61bd11326e7f85
- response sha256
- 0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
- retrieved at
- 2026-09-09T23:47:36.359220+00:00
- publication date
- display
- 2019 Jan 15
- precision
- day
- year
- 2019
- publication types
- Clinical Trial
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Preserved source evidence · Not medical advice